Treatment of chronic hepatitis C in a state correctional facility
Treatment of chronic hepatitis C in a state correctional facility
复制标题
DOI：
10.7326/0003-4819-138-3-200302040-00010
复制
发表时间：
2003-02-04
影响因子：
39.2
通讯作者：
Rich, JD
中科院分区：
文献类型：
--
作者：
Allen, SA;Spaulding, AC;Rich, JD
背景资料：在州和联邦教养机构的近200万人中，约有四分之一感染丙型肝炎病毒（HCV）。目前，在这种情况下，这种常见感染的治疗结果的报道很少。目的：描述在监禁环境中的HCV治疗。设计：回顾性，描述性观察研究。设置：罗得岛惩教署，克兰斯顿，罗得岛。患者：93名慢性HCV感染的囚犯。干预：干扰素-α与利巴韦林。测量：治疗后6个月的HCV RNA水平。结果：回复率与先前公布的社区回复率相似; 63%（50/79）的患者在治疗6个月后达到病毒清除，46%的患者在治疗6个月后达到病毒清除。57例患者中有26例在治疗后6个月达到持续缓解。被监禁人口（这是不成比例地受到成瘾和精神疾病的影响）可以有效地治疗丙型肝炎病毒感染与干扰素和利巴韦林。矫正设置可以提供一个机会，安全地治疗这两个具有挑战性的共病患者。
Background: Approximately 1 in 4 of the nearly 2 million individuals in state and federal correctional facilities are infected with hepatitis C virus (HCV). Currently, there are few reports of treatment outcomes of this common infection in this setting.Objective: To describe HCV therapy in the incarcerated setting.Design: Retrospective, descriptive observational study.Setting: Rhode Island Department of Corrections, Cranston, Rhode island.Patients: 93 inmates with chronic HCV infection.Intervention: Interferon-alpha with ribavirin.Measurements: HCV RNA levels 6 months after treatment.Results: Response rates are similar to previously published rates achieved in the community; 63% (50 of 79) of patients achieved viral clearance after 6 months of therapy, and 46% (26 of 57) achieved sustained response 6 months after treatment.Conclusion: The incarcerated population (which is disproportionately affected by addiction and psychiatric illness) can be effectively treated for HCV infection with interferon and ribavirin. The correctional setting may provide an opportunity to safely treat patients with these two challenging comorbid conditions.